INVITRO SUSCEPTIBILITY OF HELICOBACTER-PYLORI TO THE NEW ORAL CEPHALOSPORINS CEFPODOXIME, CEFTIBUTEN AND CEFIXIME

被引：18

作者：

WESTBLOM, TU

GUDIPATI, S

MIDKIFF, BR

机构：

[1] Department of Medicine, Division of Infectious Diseases, St. Louis University School of Medicine, St. Louis, 63104, Missouri

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 1990年 / 9卷 / 09期

关键词：

D O I：

10.1007/BF01964274

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The in vitro activity against 30 Helicobacter pylori strains of three new third generation cephalosporins, cefpodoxime, ceftibuten and cefixime, which can be administered orally, was determined using an agar dilution technique under microaerophilic conditions. The MIC50 and MIC90 of cefpodoxime was 0.5 and 4.0 μg/ml respectively, of ceftibuten 2.0 and 8.0 μg/ml, and of cefixime 0.06 and 0.5 μg/ml. All antibiotics showed good activity against Helicobacter pylori, cefixime having the highest activity of the three agents. © 1990 Friedr. Vieweg & Sohn Verlagsgesellschaft mbH.

引用

页码：691 / 693

页数：3

共 12 条

[1] CAMPYLOBACTER-PYLORI - THERAPY REVIEW [J].

AXON, ATR .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :35-38

[2] CEFIXIME - SPECTRUM OF ANTIBACTERIAL ACTIVITY AGAINST 16016 CLINICAL ISOLATES [J].

BARRY, AL ;

JONES, RN .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1987, 6 (10) :954-957

[3] RECURRENCE OF DUODENAL-ULCER AND CAMPYLOBACTER-PYLORI INFECTION AFTER ERADICATION [J].

BORODY, TJ ;

COLE, P ;

NOONAN, S ;

MORGAN, A ;

LENNE, J ;

HYLAND, L ;

BRANDL, S ;

BORODY, EG ;

GEORGE, LL .

MEDICAL JOURNAL OF AUSTRALIA, 1989, 151 (08) :431-&

[4] INVITRO ACTIVITIES OF NEW ORAL BETA-LACTAMS AND MACROLIDES AGAINST CAMPYLOBACTER-PYLORI [J].

GARCIARODRIGUEZ, JA ;

SANCHEZ, JEG ;

GARCIA, MIG ;

SANCHEZ, EG ;

BELLIDO, JLM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1650-1651

[5]

GOODWIN CS, 1988, LANCET, V2, P1467

[6] TRANSFER OF CAMPYLOBACTER-PYLORI AND CAMPYLOBACTER-MUSTELAE TO HELICOBACTER GEN-NOV AS HELICOBACTER-PYLORI COMB-NOV AND HELICOBACTER MUSTELAE COMB-NOV, RESPECTIVELY [J].

GOODWIN, CS ;

ARMSTRONG, JA ;

CHILVERS, T ;

PETERS, M ;

COLLINS, MD ;

SLY, L ;

MCCONNELL, W ;

HARPER, WES .

INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, 1989, 39 (04) :397-405

[7] ANTIMICROBIAL ACTIVITY, SPECTRUM, AND RECOMMENDATIONS FOR DISK DIFFUSION SUSCEPTIBILITY TESTING OF CEFTIBUTEN (7432-S, SCH-39720), A NEW ORALLY-ADMINISTERED CEPHALOSPORIN [J].

JONES, RN ;

BARRY, AL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (10) :1576-1582

[8] ANTIBACTERIAL ACTIVITIES OF CEFPODOXIME, CEFIXIME, AND CEFTRIAXONE [J].

KNAPP, CC ;

SIERRAMADERO, J ;

WASHINGTON, JA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (12) :1896-1898

[9] ACTIVITY OF CEFIXIME (FK 027) FOR RESISTANT GRAM-NEGATIVE BACILLI [J].

SMITH, SM ;

ENG, RHK .

CHEMOTHERAPY, 1988, 34 (06) :455-461

[10] GUINEA-PIG MODEL FOR ANTIBIOTIC TRANSPORT ACROSS GASTRIC-MUCOSA - INHIBITORY TISSUE CONCENTRATIONS OF CLINDAMYCIN AGAINST HELICOBACTER-PYLORI (CAMPYLOBACTER-PYLORI) FOLLOWING 2 SEPARATE DOSE REGIMENS [J].

WESTBLOM, TU ;

DURIEX, DE ;

MADAN, E ;

BELSHE, RB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (01) :25-28

← 1 2 →